TY - JOUR
T1 - Interference of bovine hemoglobin-based oxygen carrier-201 (Hemopure) on four hematology analyzers
AU - Bronkhorst-van der Helm, Marinke W.
AU - Weerkamp, Floor
AU - Huisman, Albert
AU - Huisman, Elise J.
AU - Russcher, Henk
N1 - Publisher Copyright:
© 2023 The Authors. International Journal of Laboratory Hematology published by John Wiley & Sons Ltd.
PY - 2023/12
Y1 - 2023/12
N2 - Introduction: Hemoglobin-based oxygen carriers, for example HBOC-201 (Hemopure), are aimed to bridge acute anemia when blood transfusion is not available or refused by the patient. However, since HBOC-201 appears free in plasma, it interferes with laboratory tests. This study presents an overview of HBOC-201 interference on four commonly used hematology analyzers and suggests treatment monitoring possibilities. Methods: Blood samples were spiked with therapeutic doses of HBOC-201 and nine hematology parameters were measured with the Sysmex XN-20, Siemens Advia 2120i, Abbott Alinity Hq and Abbot Cell Dyn Sapphire hematology analyzers. The results were compared to control samples and the bias was determined. Results: Most parameters, including all cell counts, hematocrit and MCV, showed a non-significant bias compared to control. However, the standard, total hemoglobin (Hb) measurement as well as MCH and MCHC showed poor agreement with control, as HBOC-201 was included in this measurement. Yet, the flow cytometry-based Hb method quantified intracellular Hb in spiked samples, excluding HBOC-201. Conclusion: Of all included hematology parameters, only total Hb and the associated MCH and MCHC suffered from interference. In contrast, the flow cytometry-based Hb measurement provided an accurate measure of intracellular Hb. The difference between total Hb and cellular Hb represents the HBOC-201 concentration and can be used to monitor HBOC-201 treatment.
AB - Introduction: Hemoglobin-based oxygen carriers, for example HBOC-201 (Hemopure), are aimed to bridge acute anemia when blood transfusion is not available or refused by the patient. However, since HBOC-201 appears free in plasma, it interferes with laboratory tests. This study presents an overview of HBOC-201 interference on four commonly used hematology analyzers and suggests treatment monitoring possibilities. Methods: Blood samples were spiked with therapeutic doses of HBOC-201 and nine hematology parameters were measured with the Sysmex XN-20, Siemens Advia 2120i, Abbott Alinity Hq and Abbot Cell Dyn Sapphire hematology analyzers. The results were compared to control samples and the bias was determined. Results: Most parameters, including all cell counts, hematocrit and MCV, showed a non-significant bias compared to control. However, the standard, total hemoglobin (Hb) measurement as well as MCH and MCHC showed poor agreement with control, as HBOC-201 was included in this measurement. Yet, the flow cytometry-based Hb method quantified intracellular Hb in spiked samples, excluding HBOC-201. Conclusion: Of all included hematology parameters, only total Hb and the associated MCH and MCHC suffered from interference. In contrast, the flow cytometry-based Hb measurement provided an accurate measure of intracellular Hb. The difference between total Hb and cellular Hb represents the HBOC-201 concentration and can be used to monitor HBOC-201 treatment.
KW - extracellular hemoglobin
KW - hematology analyzer
KW - hemoglobin-based oxygen carrier
KW - interference
KW - intracellular hemoglobin
UR - http://www.scopus.com/inward/record.url?scp=85167698022&partnerID=8YFLogxK
U2 - 10.1111/ijlh.14146
DO - 10.1111/ijlh.14146
M3 - Article
C2 - 37571820
SN - 1751-5521
VL - 45
SP - 869
EP - 874
JO - International Journal of Laboratory Hematology
JF - International Journal of Laboratory Hematology
IS - 6
ER -